Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.91 |
| ▸ | PGR | P06401 | 5/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.91 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.91 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.91 |
| ▸ | TNF | P01375 | 1/20 | 0.91 |
| ▸ | IL6 | P05231 | 1/20 | 0.91 |
| ▸ | AR | P10275 | 1/20 | 0.91 |
| ▸ | GLUL | P15104 | 1/20 | 0.91 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.91 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone SCHEMBL1270167 | 1.00 | NR3C1 (0.91) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL16094487 | 0.99 | NR3C1 (0.93) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL5504548 | 0.99 | NR3C1 (0.93) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL7514 | 0.99 | NR3C1 (0.93) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL5073648 | 0.96 | NR3C1 (0.98) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL5073644 | 0.96 | NR3C1 (0.98) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL503432 | 0.96 | NR3C1 (0.98) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL503431 | 0.96 | NR3C1 (0.98) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL23863778 | 0.95 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL2737385 | 0.95 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583972-B1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES CONTAINING ADENOSINE N1-OXIDE AS ACTIVE INGREDIENT | HAYASHIBARA CO (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-9757408-B2 | Therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient | Hayashibara Co., Ltd. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20160166599-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT | Hayashibara Co., Ltd. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-9301968-B2 | Therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient | Hayashibara Co., Ltd. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140315849-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT | Hayashibara Co., Ltd. (JP) | 2014-10-23 | — | — | US | disclosed |
| EP-2148657-B1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INT LTD (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-20130165399-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT | Hayashibara Co., Ltd. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-8445471-B2 | Process for obtaining steroidal phosphate compounds | HOVIONE INTER LIMITED (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2583972-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES CONTAINING ADENOSINE N1-OXIDE AS ACTIVE INGREDIENT | Hayashibara Co., Ltd. (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20100240916-A1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INTER LIMITED (CH) | 2010-09-23 | — | — | US | disclosed |
| US-4406883-A | SHAPES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-09-27 | — | — | US | disclosed |
| US-4292300-A | METHYL CELLULOSE, WATER, DRUG | INVERESK RESEARCH INTERNATIONAL (GB) | 1981-09-29 | — | — | US | disclosed |
| US-4265875-A | HYDROXYPROPYL METHYL CELLULOSE | INVERESK RESEARCH INTERNATIONAL (GB) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240916-A1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HSD3B1, CYP17A1, HSD3B2 | NR3C1 38/4885HIF1A 2456/4885HSD17B10 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.